Biocon has received marketing authorisation from the Drugs Controller General of India (DCGI) for Novel Biologic Itolizumab, an anti CD6 molecule, for the treatment of chronic plaque Psoriasis. It is the second Novel Biologic developed by Biocon at Asia’s largest Biotech hub in Bangalore. This approval paves the way for the launch of Biocon’s Alzumab in India, later during 2013. Alzumab is a differentiated biologic drug with a better safety profile compared to other approved biologic therapies given its low opportunistic infection rates. A novel biologic indicated for the treatment of Moderate-to-Severe Psoriasis, Alzumab will be marketed by Biocon’s Immunotherapy Division. Alzumab will be manufactured and formulated as an infusion drug at Biocon’s Biopharma manufacturing facility at Biocon Park, Bangalore. The global market size for Psoriasis is estimated to cross $8 bn by 2016.
No comments:
Post a Comment